Published in Genome Biol on May 22, 2015
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet (2015) 0.95
Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. J Pathol (2016) 0.86
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget (2016) 0.86
Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. Biol Direct (2015) 0.81
Deciphering intratumor heterogeneity using cancer genome analysis. Hum Genet (2016) 0.78
Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol (2016) 0.78
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J Gastroenterol (2016) 0.78
Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. Histopathology (2016) 0.78
Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. PLoS One (2016) 0.77
Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. BMC Cancer (2015) 0.76
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. Nat Med (2017) 0.75
Conference report from the 2015 OECI Oncology Days, Portugal, 22-24 June-tumour heterogeneity and next generation sequencing: morphology and technology. Ecancermedicalscience (2015) 0.75
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget (2016) 0.75
Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size Cohorts. Cancer Inform (2015) 0.75
Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer. J Cancer (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
The life history of 21 breast cancers. Cell (2012) 10.59
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol (2012) 4.00
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Resolving the resolution of array CGH. Genomics (2007) 3.66
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer (2007) 2.41
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer (2005) 2.02
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet (2014) 1.96
Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res (2005) 1.96
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene (2011) 1.92
Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res (2006) 1.83
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol (2012) 1.78
Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res (2006) 1.75
RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest (2009) 1.71
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer (2008) 1.66
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene (2006) 1.41
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res (2008) 1.39
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol (2013) 1.38
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med (2010) 1.38
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol (2008) 1.31
Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res (2010) 1.23
Neuregulins and cancer. Clin Cancer Res (2008) 1.21
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol (2014) 1.19
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Mol Oncol (2008) 1.16
The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol (2008) 1.14
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res (2013) 1.14
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat (2012) 1.09
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest (2012) 1.06
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Breast J (2007) 1.06
Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol (2014) 1.05
Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest (2007) 1.04
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol (2010) 0.96
Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol (2011) 0.95
DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol (2010) 0.89
The Mub1/Ubr2 ubiquitin ligase complex regulates the conserved Dsn1 kinetochore protein. PLoS Genet (2013) 0.86
Epistatic interactions and drug response. J Pathol (2014) 0.85
Breast cancer intra-tumor heterogeneity. Breast Cancer Res (2014) 1.16